Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Australia To Fund Mekinist, Xalkori But More Evidence Will Be Needed

This article was originally published in Scrip

Executive Summary

In another example of reimbursement agencies agreeing to pay for expensive new drugs in exchange for a commitment to provide more evidence of real clinical value, two major new anticancers from Novartis and Pfizer have been recommended for funding by the Australian Pharmaceutical Benefits Scheme under managed entry schemes. The agreements include a commitment to provide more convincing data with the possibility of a price cut if the terms of the schemes are not met.

You may also be interested in...

How To Use Digital Technology For EU Drug Approvals

Early interaction with the European Medicines Agency is recommended if companies are planning to incorporate digital technologies into their drug development plans. 

New Gavi Fund To Guarantee Global Market For COVID-19 Vaccines

The latest global vaccines summit has seen the launch of a new mechanism designed to spur the development of new coronavirus vaccines and ensure they are made available, particularly in low- and middle-income countries.

EU Unveils Ambitions To ‘Future-Proof’ Entire Drug Regulatory Framework

Ambitious efforts to make the EU more resilient to future challenges, such as health threats, drug supply problems, scientific advances and growing medicine costs, have taken a step forward with the publication of a roadmap for a wide-ranging Pharmaceutical Strategy to be adopted by the European Commission later in the year.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts